PP405 in Alopecia: An Emerging Molecule Worth Investigating

    January 2026 in “ Journal of Community Medicine and Health Solutions ”
    Jawairya Muhammad Hussain, Mahnoor Khan, Shaikh Sameed, Areej Imran
    Studysummary In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on communitymedjournal.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Gender Differences in Adverse Effects and Dosing Practices of Low-Dose Oral Minoxidil for Androgenetic Alopecia: A Retrospective Analysis of 310 Patients Skin Appendage Disorders · 2024
    2. Clinical Efficacy and Safety of Low-Dose Oral Minoxidil Versus Topical Solution in the Improvement of Androgenetic Alopecia: A Randomized Controlled Trial Journal of Cosmetic Dermatology · 2023
    3. Androgenetic Alopecia: Therapy Update Drugs · 2023
    4. Treatment Options for Androgenetic Alopecia: Efficacy, Side Effects, Compliance, Financial Considerations, and Ethics Journal of Cosmetic Dermatology · 2021
    5. Alopecia Types, Current and Future Treatment Journal of dermatology & cosmetology · 2021